AMRI Becomes Curia
12.7.2021 04:00:00 EEST | Business Wire | Press release
Albany Molecular Research, Inc. (AMRI), a leading global contract research, development and manufacturing organization serving the pharmaceutical and biopharmaceutical industries, today announced that it is changing its name to Curia, effective July 12, 2021. The new name reinforces the company’s strategic positioning as an end-to-end global CDMO, applying its scientific expertise and extensive capabilities from research and development (R&D) through to commercial manufacturing to enable its pharmaceutical and biotechnology customers to advance important new products that improve lives. Along with the name change, the company is introducing a new brand identity including a new website: CuriaGlobal.com.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210711005012/en/
The name Curia is derived from a Latin word for purposeful assembly and references Curia’s patient-inspired mission. The company recently celebrated three decades of growth since its founding in Albany, New York. Today, Curia offers a global suite of R&D and commercial manufacturing capabilities, with industry-leading expertise to help its customers accelerate the journey from idea to impact. Curia employs more than 3,000 people in 21 locations around the world, including more than 600 chemists, 70 biologists, 225 senior scientists and approximately 400 quality and regulatory specialists. The company’s ongoing commitment to science that scales is demonstrated by its 564 active patents and its production of more than 20 treatments included on the list of essential medicines from the World Health Organization.
“Our new name reflects the assembled deep expertise of our people, the breadth of our products, services and solutions, and our relentless determination to help customers advance from curiosity to cure,” said Curia Chairman and CEO John Ratliff. “Our new brand honors our foundation in research and innovation while creating a platform for our ambitions of life-changing science so we can make ever-growing contributions to improving patients’ lives. Over the past three decades we have broadened and deepened our capabilities to become a leading provider of CDMO solutions. Today marks the beginning of the next chapter in our history.”
About Curia
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,100 employees at 21 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210711005012/en/
Contact information
Corporate:
Sue Zaranek
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com
Media Communications:
Debra Harrsch
Brandwidth Solutions LLC
+1 215 997 8575
dharrsch@bwsmarketing.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Austrian Broadband Operator Deploys Vecima’s Entra ® vCMTS and Remote PHY Devices to Advance its Next-Generation DOCSIS ® Network13.5.2026 14:45:00 EEST | Press release
Vecima Networks Inc. (TSX: VCM) and Witke today announced that an Austrian broadband operator is deploying the Entra® virtualized Cable Modem Termination System (vCMTS) as the DOCSIS® platform for its Distributed Access Architecture (DAA) evolution. The deployment, led by Witke, enables advanced reliability, scalable capacity expansion over time, and a clear migration path toward DOCSIS 4.0 broadband services. After extensive system planning and evaluation, the operator selected a vCMTS and Remote PHY (R-PHY) architecture to align with its long-term network roll-out strategy and migration requirements. The deployment provides the flexibility to modernize the network in phases while reducing space, power, and cooling requirements across the operator’s infrastructure. Entra vCMTS establishes a new standard for simplified, virtualized Cable Access, combining a modern microservices architecture with commercial off-the-shelf (COTS) hardware to deliver next-generation flexibility while enhan
Vecima, Incognito, and BM COM Announce Turnkey Fiber Broadband Solutions at ANGA COM 202613.5.2026 14:30:00 EEST | Press release
Vecima Networks Inc., Incognito Software Systems Inc., and BM COM s.r.o., today announced a strategic collaboration to deliver a fully integrated, turnkey fiber broadband solution, which will be showcased at ANGA COM 2026, May 19–21 in Cologne, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513492655/en/ The joint solution brings together best-in-class fiber access infrastructure, advanced service orchestration, and in-market deployment expertise into a unified, interoperable Broadband-in-a-Box platform without requiring single vendor lock-in. Designed to simplify and accelerate fiber broadband rollouts, the solution enables operators—particularly regional and emerging providers—to deploy scalable, high-performance networks with reduced complexity and faster time to revenue. The joint Vecima, Incognito, and BM COM Broadband-in-a-Box solution integrates: Vecima’s Entra® XGS-PON platform, delivering scalable, high-
Veristat Launches AI Biostatistics Platform, Cutting Clinical Trial Data Readout Time from 5 Weeks to 5 Days * Without Regulatory Risks13.5.2026 14:05:00 EEST | Press release
Veristat™, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced the launch of InStat™ by Veristat. InStat is the clinical research industry’s first zero-code, fully automated biostatistics solution, reducing manual effort to speed time to approval with every output backed by validated statistical engines and expert biostatistician review. It delivers submission-ready tables, listings, and figures (TLF) in five days or less*, rather than the four to six weeks sponsors typically wait after database lock, while maintaining the highest quality data. Veristat will begin using InStat to deliver biostatistics services in June. Clene Nanomedicine is the first clinical trial sponsor whose work was delivered using InStat, with NfL biomarker analyses supporting their planned 2026 New Drug Application (NDA). "Following recent FDA interactions, we are advancing our NDA submission for CNM-Au8 with NfL biomarker concordance evidence as a core compon
Carta Launches Carta Law with Acquisition of Avantia13.5.2026 14:01:00 EEST | Press release
Carta, the agentic enterprise resource planning (ERP) platform for private capital, today announced it has acquired Avantia, a leading AI-powered legal and compliance law firm for asset managers. The acquisition launches Carta Law—the largest AI-native, integrated legal and compliance solution for private markets—unifying legal and compliance workflows with fund operations on a single platform. Private capital firms have long operated with fragmented infrastructure, with fund administration, compliance, and legal services spread across separate vendors. Deal teams wait days for NDAs. Limited partner onboarding to new funds is delayed by KYC backlogs. General counsels lose visibility into legal spend or institutional precedent. As deal velocity increases and regulatory complexity grows, this fragmentation becomes a competitive disadvantage and operational barrier for funds. With the acquisition of Avantia and the introduction of Carta Law, the industry will have a single-platform soluti
Amazfit Unveils the Cheetah 2 Ultra: The Performance Trail Running Watch Built to Master the Toughest Mountain Trails13.5.2026 14:00:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the Cheetah 2 Ultra. Building on the momentum of the recently launched Cheetah 2 Pro—designed for road marathoners—the Ultra is a specialized instrument for trail runners who measure success in elevation, unpredictable terrain, and hours spent on the move. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513230718/en/ Built for ultra distances and mountain racing, the Cheetah 2 Ultra combines long battery life, precision navigation, and advanced training insights to carry more distance and control more load. Amazfit’s Cheetah 2 Ultra is built for runners who prepare for ultra distances and mountain races, boasting 33-hour trail running optimized GPS battery life, full-color contour maps, Grade 5 titanium construction, and advanced training and recovery insights. Amazfit designed the Cheetah 2 Ultra to support the preparation required for lo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom